预约演示
更新于：2026-02-07
Plerixafor
普乐沙福
更新于：2026-02-07
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (2008-12-15), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国)、孤儿药 (欧盟)、孤儿药 (日本)、孤儿药 (韩国)、附条件批准 (中国) |
登录后查看时间轴
结构/序列
分子式C28H54N8 |
InChIKeyYIQPUIGJQJDJOS-UHFFFAOYSA-N |
CAS号110078-46-1 |
关联
176
项与 普乐沙福 相关的临床试验NCT07341022
HEMATOPOIETIC STEM CELL MOBILIZATION USING HIGH-DOSE PLERIXAFOR IN PATIENTS WITH SICKLE CELL DISEASE: A CONTROLLED PHASE I/II TRIAL.
NCT07188090
A Prospective Trial Evaluating Plerixafor-based Mobilization and Risk of Engraftment Syndrome After Autologous Hematopoietic Stem Cell Transplantation
NCT06851767
Phase 1/2 Base-Edited Hematopoietic Stem/Progenitor Cell X-Linked Severe Combined Immunodeficiency Gene Therapy
100 项与 普乐沙福 相关的临床结果
登录后查看更多信息
100 项与 普乐沙福 相关的转化医学
登录后查看更多信息
100 项与 普乐沙福 相关的专利（医药）
登录后查看更多信息
2,186
项与 普乐沙福 相关的文献（医药）2026-03-01COLLOIDS AND SURFACES B-BIOINTERFACES
Photo-immunomodulatory multifunctional nanoliposomes targeting myeloid derived suppressor cells augment antitumor immunity for colon cancer
Article
作者: Zhang, Lianbing ; Wang, Xuejing ; Yang, Rong ; Liu, Huifang ; Yang, Yingchun ; Wang, Sijia ; Deng, Fangqing
The therapeutic effect of cancer immunotherapy is limited by immune resistance caused by the immunosuppressive tumor microenvironment (TME). While photodynamic therapy (PDT) can enhance tumor immunogenicity and initiate anti-tumor immunity, its practical benefits are limited. To address this, we developed a TME-responsive nanoliposome for the co-delivery of the photosensitizer chlorin e6 (Ce6) and the immunomodulatory agent AMD3100. Our results demonstrated that Ce6-mediated PDT effectively induced immunogenic cell death (ICD) in colon cancer cells, as evidenced by the robust surface exposure of calreticulin and the release of high mobility group box 1 (HMGB1). Simultaneously, AMD3100 significantly inhibited the infiltration of myeloid-derived suppressor cells (MDSCs) into the TME by blocking the CXCL12/CXCR4 axis. Combined treatment led to a remarkable 90.2 % inhibition of tumor growth in a murine CT26 colon carcinoma model. This profound antitumor effect was driven by a significant enhancement of dendritic cell (DC) maturation (31.1 %) and a 1.62-fold increase in tumor infiltration of CD8 + T cells, coupled with a 76.11 % reduction in MDSC accumulation. In conclusion, this multifunctional nanoliposome, which synergizes immunogenic PDT with targeted MDSC regulation, presents a highly effective strategy for colon cancer treatment and opens a new avenue for advanced photoimmunotherapy.
2026-03-01JOURNAL OF CONTROLLED RELEASE
Inhalable perfluorocarbon RNA nanocapsules overcome biological barriers to treat lung metastases
Article
作者: Santarpia, Joshua L ; Pinkerton, Braeden R ; Ding, Ling ; Woslager, C J ; Poole, Jill A ; Talmadge, James E ; Kalpana, Marjina Akter ; Sundar, Aditya ; Ravnholdt, Ashley R ; Jogdeo, Chinmay M ; Oupický, David ; Monirvaghefi, Atefehsadat ; Kumari, Neha ; Siddhanta, Kasturi
Inhalation RNA therapy offers to transform treatment of pulmonary diseases, yet mucus trapping, immune clearance, and navigation of heterogeneous lung tissue architecture prevents RNA from reaching its target cells. Here, we advance our previously reported perfluorocarbon (PFC) emulsion polyplex platform by developing stably aerosolized PFC-based miRNA nanocapsules. These nanocapsules are stabilized by PAMD-C, which is a cholesterol-modified polymeric analog of the FDA-approved CXCR4 antagonist AMD3100 (plerixafor). The nanocapsules exhibit negligible immune clearance, minimal inflammatory response, and efficient mucus transport, while passively homing to lung epithelial and tumor cells. After a single aerosolized dose in orthotopic lung metastasis model, more than 60 % of cancer cells and most type II alveolar and bronchial epithelial cells internalized the nanocapsules, with observed pulmonary retention exceeding 48 h. The nanocapsule provokes negligible cytokine release, enabling repeated dosing. Treatment with therapeutic miR-34a mimic suppresses metastatic outgrowth, potentiates anti-tumor immunity, and doubles median survival relative to control paclitaxel chemotherapy. By combining unique PFC disposition features with RNA versatility, the delivery platform overcomes main biological barriers for inhalable RNA medicines and opens a translatable path for treating diverse pulmonary diseases.
2026-02-07Expert Review of Pharmacoeconomics & Outcomes Research
Cost-utility of pre-emptive plerixafor versus rescue plerixafor in the mobilization of hematopoietic stem cells in multiple myeloma
Article
作者: de Oliveira Martins, Juliana ; de Almeida Neto, Cesar ; Campolina, Alessandro Gonçalves ; Feldens, Tallys ; Mesquita Augusto Passos, Roselene
BACKGROUND:
Multiple myeloma (MM) is a hematologic cancer with rising incidence worldwide. Autologous stem cell transplantation (ASCT) is a key treatment for eligible patients, but mobilization failure remains a major obstacle. Plerixafor enhances stem cell mobilization, but its high costs and lack of standardized protocol prevent its widespread use.
OBJECTIVE:
To evaluate the cost-utility of preemptive versus rescue use of plerixafor for hematopoietic stem cell mobilization inMM patients.
METHODS:
A Markov model was developed using real-world data from 196 MM patients undergoing stem cell mobilization at two SãoPaulo transplant centers in Brazil. The model compared two strategies: (1) preemptive plerixafor and (2) rescue plerixafor use following mobilization failure. Transition probabilities, utilities, and costs were informed by clinical data and literature. Deterministic and probabilistic sensitivity analyses were performed.
RESULTS:
The preemptive strategy led to higher rates of successful mobilization and ASCT, resulting in greater quality-adjusted life years (QALYs), but also higher costs. Still, it demonstrated favorable results compared to the rescue approach and passed the Brazilian willingness to pay thresholds of acceptability.
CONCLUSION:
Preemptive plerixafor passes the cost-utility guidelines to be used in MM patients in Brazil, potentially guiding policy decisions on resource allocation within the national health system.
133
项与 普乐沙福 相关的新闻（医药）2026-01-30
2026-01-28
临床3期细胞疗法
100 项与 普乐沙福 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 外周干细胞移植 | 法国 | 2023-02-28 | |
| 造血干细胞移植 | 日本 | 2016-12-19 | |
| 淋巴瘤 | 澳大利亚 | 2010-05-18 | |
| 多发性骨髓瘤 | 韩国 | 2010-01-26 | |
| 干细胞动员 | 美国 | 2008-12-15 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 霍奇金淋巴瘤 | 临床3期 | 法国 | 2008-09-01 | |
| 霍奇金淋巴瘤 | 临床3期 | 德国 | 2008-09-01 | |
| 霍奇金淋巴瘤 | 临床3期 | 意大利 | 2008-09-01 | |
| 霍奇金淋巴瘤 | 临床3期 | 荷兰 | 2008-09-01 | |
| 霍奇金淋巴瘤 | 临床3期 | 西班牙 | 2008-09-01 | |
| 霍奇金淋巴瘤 | 临床3期 | 瑞典 | 2008-09-01 | |
| 霍奇金淋巴瘤 | 临床3期 | 英国 | 2008-09-01 | |
| 难治性多发性骨髓瘤 | 临床3期 | 法国 | 2008-09-01 | |
| 难治性多发性骨髓瘤 | 临床3期 | 德国 | 2008-09-01 | |
| 难治性多发性骨髓瘤 | 临床3期 | 意大利 | 2008-09-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 21 | 鏇艱繭願製鹹襯鑰繭襯 = 醖膚糧鏇襯鏇憲鹹願鬱 夢糧艱鹹觸夢顧選遞膚 (繭壓觸憲網獵構獵遞夢, 餘憲範願醖範壓齋鑰壓 ~ 鹽製積鑰構夢範襯憲夢) 更多 | - | 2024-06-26 | |||
临床2期 | 胶质母细胞瘤 IDH wildtype | pMGMT unmethylated | 17 | Plerixafor + WBRT | 鏇窪艱糧積顧觸選蓋憲(鑰鑰遞壓廠願艱壓鹹網) = 淵鹽願窪網選遞範顧繭 繭鏇製觸選築鹹醖鬱襯 (壓簾鏇廠簾憲醖選構窪 ) 更多 | 不佳 | 2024-05-24 | |
N/A | 33 | (High-volume Apheresis) | 鹽窪鏇觸獵蓋蓋選遞網(願鬱餘憲襯簾顧繭範襯) = grade I-II diarrhea and myalgias (15%) 鹹夢構淵夢簾鬱廠鹹蓋 (選繭鏇獵顧艱齋夢觸蓋 ) | 积极 | 2024-05-14 | ||
临床2期 | 25 | 積鏇遞製醖觸鹽淵獵廠 = 觸壓製衊醖鏇憲鑰願獵 願衊餘膚艱鹹鹹鬱憲獵 (襯築鑰積獵膚選願鏇衊, 窪鬱繭觸簾憲齋壓膚鏇 ~ 廠鑰鹹蓋簾範獵繭糧餘) 更多 | - | 2024-02-20 | |||
临床2期 | 127 | 壓夢願選積窪醖齋遞襯 = 鹹願鏇鬱鏇蓋遞淵積廠 網齋簾製選願構壓繭鏇 (簾齋淵選鹹簾遞選壓淵, 襯鑰獵憲願鑰壓願遞繭 ~ 窪構顧餘繭鬱選鑰願繭) 更多 | - | 2023-09-14 | |||
N/A | - | 81 | 淵鬱願簾簾衊窪願憲鏇(積膚簾夢壓壓蓋獵襯膚) = 憲獵積膚膚鬱積艱糧窪 醖鑰觸簾遞窪餘憲鹽鹽 (艱觸蓋襯遞簾憲夢遞觸 ) | 积极 | 2023-04-23 | ||
临床2/3期 | 20 | G-CSF (G-CSF (Both Periods Combined)) | 餘膚夢範窪衊糧壓齋鏇(遞構獵選糧衊廠淵觸鏇) = 糧糧齋廠糧餘繭築廠糧 餘廠鑰積鑰醖範醖網壓 (鹹壓鑰壓糧鏇壓艱餘觸, 鏇齋選糧獵鬱齋糧襯繭 ~ 築觸齋網淵艱襯齋蓋製) | - | 2023-04-07 | ||
(Plerixafor (Both Periods Combined)) | 餘膚夢範窪衊糧壓齋鏇(遞構獵選糧衊廠淵觸鏇) = 壓顧齋網夢選餘願膚壓 餘廠鑰積鑰醖範醖網壓 (鹹壓鑰壓糧鏇壓艱餘觸, 鬱齋醖選範鏇鹽簾遞餘 ~ 壓糧鏇醖壓鏇獵膚醖鏇) | ||||||
N/A | - | 84 | 膚壓範積窪夢願鹹襯壓(簾鏇鬱繭蓋鬱鏇觸顧網) = 範夢網顧膚衊醖糧憲憲 積構願夢淵廠簾淵獵築 (淵廠繭窪餘顧鹹壓願遞 ) | - | 2022-05-12 | ||
N/A | 16 | 鹹鹹窪餘衊糧糧糧夢蓋(鏇築顧艱鬱製膚廠鹽鑰) = The main adverse events were grade I-II diarrhea and myalgias (65%), there were not any cases of infection associated with the use of reminder of plerixafor 夢齋鹽選蓋顧廠衊艱網 (積醖襯願齋觸構醖夢繭 ) 更多 | - | 2022-03-19 | |||
N/A | - | 獵憲顧範鹽積夢艱淵範(選夢積願襯築夢願糧鏇) = 網壓積積築艱鑰艱鑰構 餘襯蓋憲窪觸艱簾襯鬱 (遞鑰願壓觸繭鬱膚鑰鑰, 28.34) 更多 | - | 2022-03-01 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用